Skip to main content
Equibles
RCEL logo

RCEL · AVITA Medical, Inc. · Metrics

Track RCEL — free

Use RCEL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RCEL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.65 -1.06 (-6.34%) At close · Oct 30 Q2 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on the Company's liquidity position and the Company's current forecast of operating results and cash flows, management determined there is substantial doubt about the Company's ability to continue as a going concern over the next twelve months following the date of issuance of these Consolidated Financial Statements due to the Company's debt repayment obligations, recurring losses, and historical negative cash flows.”
View the 10-Q filed Aug 6, 2026
Market Cap
$484.01M
Shares
30.93M
Volume · Oct 30 597.05K Avg daily vol (3M) 484.46K

RCEL metrics

78 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$15.65
Market cap
$484.01M

Price action

20 metrics
Price change (1W)
+0.9%
Price change (30D)
+30.3%
Price change (3M)
+255.7%
Price change (6M)
+252.5%
Price change (YTD)
+353.6%
Price change (1Y)
+326.4%
Trailing year
Price change (5Y)
-5.0%
52-week high
$16.71
52-week low
$3.27
Change from 52-week high
-6.3%
Change from 52-week low
+378.6%
Annualized volatility
95.4%
Annualized volatility (3M)
142.8%
Beta
1.7
RSI (14D)
66.2
Price vs SMA 50
+28.2%
Price vs SMA 200
+138.8%
Avg volume (3M)
484,461
Relative volume
1.2
Average dollar volume
$5.13M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
30.93M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
7.0×
reciprocal yield 14.2%
EV / EBITDA
—
EV / EBIT
—
P / sales
6.7×
reciprocal yield 14.9%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-8.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
81.6%
Operating margin
-46.6%
Trailing 12 months
Net margin
-57.0%
Gross profit (TTM)
$61.68M
Operating profit (TTM)
−$35.22M
Net income (TTM)
−$43.08M
Trailing 12 months
Diluted EPS (TTM)
$-1.43
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$2.52
Gross profit per diluted share (TTM)
$2.05
Operating profit per diluted share (TTM)
$-1.18
EBITDA per diluted share (TTM)
$-1.09
Net income per diluted share (TTM)
$-1.44
Operating cash flow per diluted share (TTM)
$-0.81
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.67
Stock compensation per diluted share (TTM)
$0.24
Book value per share
$-0.54

Growth

11 metrics
Revenue growth YoY
+17.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$75.63M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+16.6%
Year over year · more shares
Revenue CAGR (3Y)
+27.7%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-90.2%
Debt / equity
—
Current ratio
0.4
EBITDA (TTM)
−$32.71M
Free cash flow (TTM)
—
Quick ratio
0.3
Interest coverage
-6.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$24.80M
Latest balance sheet
Cash & equivalents
$9.14M
Total assets
$47.78M
Total debt
$42.98M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$24.23M
Capital expenditures (TTM)
$387,000
R&D (TTM)
$20.14M
SG&A (TTM)
—
Stock compensation (TTM)
$7.24M
R&D / revenue
26.6%
Stock compensation / revenue
9.6%

Ownership (13F)

9 metrics
13F filers
74
13F filer change QoQ
-6
Institutional ownership
16.1%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
4.3%
Private-fund adviser ownership
3.9%
Active holders' share change QoQ
+27.1%
Holder tenure
7.8
Price vs estimated holder cost
-49.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
6.8%

Short interest

3 metrics
Short interest
9.2%
Latest settlement · 7.6 days to cover
Days to cover
7.6d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1762303 CUSIP 05380C102 13F (30d) 11 filings 11 filers Visit website